产品说明
包装
5, 25 mg in glass bottle
生化/生理作用
BAY W1807, the active metabolite of BAY R3401, inhibits muscle glycogen phosphorylase a and b. In gel-filtered liver extracts, racemic BAY U6751 (containing active BAY W1807) was tested for inhibition of phosphorylase in the glycogenolytic (in which only phosphorylase a is active). In liver extracts, BAY U6751 (0.9-36 μmol/L) inhibited glycogen synthesis by phosphorylase b (notwithstanding the inclusion of AMP), but not by phosphorylase a. Inhibition of phosphorylase-a-catalyzed glycogenolysis was partially relieved by AMP (500 μmol/L). BAY U6751 facilitated phosphorylase-a dephosphorylation. Isolated hepatocytes and perfused livers were tested for BAY R3401-induced changes in phosphorylase-a:b ratios and glycogenolytic output.
特点和优势
This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
注意
Light sensitive. Store in amber vials.
基本信息
经验(实验)分子式 | C20H20ClNNa2O6 · xH2O |
分子量 | 451.81 (anhydrous basis) |
MDL编号 | MFCD08705410 |
PubChem化学物质编号 | 24891730 |
NACRES | NA.77 |
产品性质
质量水平 | 100 |
测定 | ≥98% (HPLC) |
形式 | solid |
储存条件 | protect from light |
颜色 | white |
溶解性 | H2O: >8 mg/mL |
创始人 | Bayer |
储存温度 | 2-8℃ |
SMILES string | [Na+].[Na+].[H]O[H].CCN1C(C)=C(C(c2ccccc2Cl)C(C([O-])=O)=C1C([O-])=O)C(=O)OC(C)C |
InChI | 1S/C20H22ClNO6.2Na.H2O/c1-5-22-11(4)14(20(27)28-10(2)3)15(12-8-6-7-9-13(12)21)16(18(23)24)17(22)19(25)26;;;/h6-10,15H,5H2,1-4H3,(H,23,24)(H,25,26);;;1H2/q;2*+1;/p-2 |
InChI key | QECLOEJXLYHXNF-UHFFFAOYSA-L |
安全信息
象形图 | |
警示用语: | Warning |
危险声明 | H315 - H319 - H335 |
预防措施声明 | P302 + P352 - P305 + P351 + P338 |
危险分类 | Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3 |
靶器官 | Respiratory system |
储存分类代码 | 11 - Combustible Solids |
WGK | WGK 3 |
闪点(F) | Not applicable |
闪点(C) | Not applicable |
个人防护装备 | dust mask type N95 (US), Eyeshields, Gloves |